v3.26.3
Collaboration Agreements (Details)
 1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended 36 Months Ended 87 Months Ended
Aug. 31, 2026
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
USD ($)
performanceObligation
product
Apr. 30, 2023
USD ($)
Jul. 31, 2022
Jan. 31, 2021
USD ($)
target
performanceObligation
Jun. 30, 2019
USD ($)
candidate
target
Mar. 31, 2024
Aug. 31, 2026
USD ($)
Aug. 31, 2025
USD ($)
May 31, 2024
USD ($)
Aug. 31, 2026
USD ($)
Aug. 31, 2025
USD ($)
Aug. 31, 2026
USD ($)
Aug. 31, 2026
USD ($)
Nov. 30, 2025
USD ($)
Mar. 31, 2023
target
Dec. 31, 2019
target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Revenue                         $ 673,064,000 $ 7,894,000   $ 688,359,000 $ 70,403,000          
Deferred revenue, current $ 8,610,000                       8,610,000     8,610,000   $ 8,610,000 $ 8,610,000 $ 17,580,000    
Deferred collaboration funding, current 22,233,000                       22,233,000     22,233,000   22,233,000 22,233,000 0    
Cost sharing allocation offset to research and development expenses                         79,260,000 86,120,000   251,049,000 233,879,000          
Prepaid expenses and other current assets $ 35,437,000                       35,437,000     35,437,000   35,437,000 35,437,000 13,878,000    
License revenue                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Revenue                         653,156,000 0   $ 653,156,000 30,000,000          
Gilead Agreement                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Drug targets | target                     5                   1  
Collaboration agreement contract term                     5 years         5 years            
Term extension 2 years 2 years     2 years             2 years                    
Extension payment                             $ 15,000,000.0       15,000,000.0      
Extension fee $ 10,000,000.0 $ 10,000,000.0                                        
Number of drug candidates | candidate                     1                      
Upfront payment                     $ 45,000,000.0                      
Upfront payment of additional fees                     $ 3,000,000.0                      
Research milestones payments received                                     47,000,000.0      
Clinical milestone payment                                     5,000,000.0      
Research and development milestone payments 370,000,000.0                       370,000,000.0     $ 370,000,000.0   370,000,000.0 370,000,000.0      
Target licensing and reservation payments 50,000,000.0                       50,000,000.0     50,000,000.0   50,000,000.0 50,000,000.0      
Certain sales milestones payments 900,000,000.0                       900,000,000.0     900,000,000.0   900,000,000.0 900,000,000.0      
Expiration term                     10 years                      
Variable consideration included in transaction price                               47,000,000.0            
Collaboration revenue recognized from opening contract liability                         200,000 2,100,000   3,800,000 5,500,000          
Recorded deferred revenue 10,000,000.0                       10,000,000.0     10,000,000.0   10,000,000.0 10,000,000.0 3,800,000    
Deferred revenue, current 4,700,000                       4,700,000     4,700,000   4,700,000 4,700,000      
Gilead Agreement | License revenue                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Revenue               $ 20,000,000.0                     20,000,000.0      
Gilead Agreement | Maximum                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Number of drug candidates | candidate                     2                      
Additional payments 1,300,000,000                       1,300,000,000     1,300,000,000   1,300,000,000 1,300,000,000      
Sanofi Agreement                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Drug targets | target                   5                       3
Term extension           2 years                                
Revenue                         10,000,000.0 0   12,000,000.0 16,100,000          
Upfront payment                   $ 55,000,000.0                        
Expiration term                   10 years                        
Variable consideration included in transaction price                   $ 20,000,000.0                        
Recorded deferred revenue 0                       0     $ 0   0 0 0    
Additional payment received to exercise option to expand number of targets                   $ 22,000,000.0                        
Additional drug targets | target                   2                        
Number of performance obligations | performanceObligation                   1                        
Contractual initial research period                               4 years 3 months            
Revenue recognized                           0     9,100,000          
Performance obligation satisfied                           0     6,400,000          
Sanofi Agreement | Sanofi Agreement                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Research milestones payments received                               $ 22,000,000.0            
Research and development milestone payments 187,000,000.0                       187,000,000.0     187,000,000.0   187,000,000.0 187,000,000.0      
Certain sales milestones payments 500,000,000.0                       500,000,000.0     500,000,000.0   500,000,000.0 500,000,000.0      
Regulatory milestone payments 250,000,000.0                       250,000,000.0     250,000,000.0   250,000,000.0 250,000,000.0      
Sanofi Agreement | License revenue                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Revenue     $ 15,000,000.0 $ 15,000,000.0                       30,000,000.0            
Sanofi Agreement | Maximum                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Extended research term                 5 years 3 months                          
Sanofi Agreement | Maximum | Sanofi Agreement                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Additional payments 937,000,000.0                       937,000,000.0     937,000,000.0   937,000,000.0 937,000,000.0      
Sanofi Agreement | Minimum                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Extended research term                 1 year                          
Pfizer                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Revenue                         9,700,000 $ 5,800,000   19,400,000 $ 13,800,000          
Variable consideration included in transaction price             $ 22,000,000.0                              
Recorded deferred revenue 9,400,000                       9,400,000     9,400,000   9,400,000 9,400,000 23,800,000    
Deferred revenue, current 3,900,000                       3,900,000     3,900,000   3,900,000 3,900,000 13,800,000    
Number of performance obligations | performanceObligation             1                              
Contractual initial research period             4 years                              
Revenue recognized                         4,100,000     13,800,000            
Performance obligation satisfied                         5,200,000     4,200,000            
Products arising from collaboration | product             2                              
Contract assets 7,000,000.0                       7,000,000.0     7,000,000.0   7,000,000.0 7,000,000.0 $ 5,000,000.0    
Pfizer | Pfizer                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Upfront payment             $ 60,000,000.0                              
Research milestones payments received                                   15,000,000.0        
Additional payments 3,400,000,000                       3,400,000,000     3,400,000,000   3,400,000,000 3,400,000,000      
Research and development milestone payments 621,000,000.0                       621,000,000.0     621,000,000.0   621,000,000.0 621,000,000.0      
Target licensing and reservation payments 19,500,000                       19,500,000     19,500,000   19,500,000 19,500,000      
Certain sales milestones payments 1,800,000,000                       1,800,000,000     1,800,000,000   1,800,000,000 1,800,000,000      
Regulatory milestone payments 873,000,000.0                       873,000,000.0     873,000,000.0   873,000,000.0 873,000,000.0      
Pfizer | Maximum                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Contractual initial research period             6 years                              
Pfizer | Minimum                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Contractual initial research period             4 years                              
Roche Agreement                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Percentage of development cost   40.00%                                        
Roche Agreement | Roche                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Percentage of development cost   60.00%                                        
Upfront payment received   $ 700,000,000.0                           46,800,000            
Total additional payment 1,600,000,000                       1,600,000,000     1,600,000,000   1,600,000,000 1,600,000,000      
Consideration amount                         1,200,000     1,200,000            
Deferred collaboration funding 45,600,000                       45,600,000     45,600,000   45,600,000 45,600,000      
Deferred collaboration funding, current 22,200,000                       22,200,000     22,200,000   22,200,000 22,200,000      
Cost sharing allocation offset to research and development expenses                         3,300,000     3,300,000            
Prepaid expenses and other current assets 3,300,000                       3,300,000     3,300,000   3,300,000 3,300,000      
Roche Agreement | Roche | Development Milestone                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Total additional payment 290,000,000.0                       290,000,000.0     290,000,000.0   290,000,000.0 290,000,000.0      
Roche Agreement | Roche | Regulatory Milestones                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Total additional payment 280,000,000.0                       280,000,000.0     280,000,000.0   280,000,000.0 280,000,000.0      
Roche Agreement | Roche | Launch Milestones                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Total additional payment 300,000,000.0                       300,000,000.0     300,000,000.0   300,000,000.0 300,000,000.0      
Roche Agreement | Roche | Sales Milestones                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Total additional payment $ 710,000,000.0                       710,000,000.0     710,000,000.0   $ 710,000,000.0 $ 710,000,000.0      
Roche Agreement | License revenue | Roche                                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                            
Upfront payment received                         $ 653,200,000     $ 653,200,000